Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.

[1]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[2]  M. Porter,et al.  What is value in health care? , 2010, The New England journal of medicine.

[3]  Craig C Earle,et al.  How does initial treatment choice affect short‐term and long‐term costs for clinically localized prostate cancer? , 2010, Cancer.

[4]  A. Rees,et al.  Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. , 2010, Health technology assessment.

[5]  Yair Lotan,et al.  Economics of robotics in urology , 2010, Current opinion in urology.

[6]  E. Lamont,et al.  Evaluation of trends in the cost of initial cancer treatment. , 2008, Journal of the National Cancer Institute.

[7]  Pascal Pommier,et al.  Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. , 2007, International journal of radiation oncology, biology, physics.

[8]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[9]  Yair Lotan,et al.  The new economics of radical prostatectomy: cost comparison of open, laparoscopic and robot assisted techniques. , 2004, The Journal of urology.

[10]  Michael J. Zelefsky,et al.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer , 2004 .

[11]  L. Potters,et al.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[12]  David J Brenner,et al.  What hypofractionated protocols should be tested for prostate cancer? , 2002, International journal of radiation oncology, biology, physics.

[13]  Jonathan H Sunshine,et al.  Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D Yan,et al.  An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[15]  Tammy O. Tengs,et al.  Five-hundred life-saving interventions and their cost-effectiveness. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[16]  G. Gustafson,et al.  Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[17]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[18]  P. McMahon,et al.  Institute for Clinical and Economic Review Final Appraisal Document:Brachytherapy and Proton Beam Therapy for Treatment of ClinicallyLocalized, Low-Risk Prostate Cancer , 2008 .

[19]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[20]  G. Gustafson,et al.  Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. , 2001, International journal of radiation oncology, biology, physics.

[21]  J. Kirkpatrick.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, Journal of insurance medicine.